Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Telescope Innovations's 3-Year RORE % for the quarter that ended in May. 2026 was 38.10%.
The industry rank for Telescope Innovations's 3-Year RORE % or its related term are showing as below:
TELIF's 3-Year RORE % is ranked better than 88.07% of 1291
companies
in the Biotechnology industry
Industry Median: -11.44
vs TELIF: 38.10
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Telescope Innovations 3-Year RORE % Related Terms
Telescope Innovations 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Telescope Innovations's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TELIF vs VRTX, REGN, ALNY: 3-Year RORE % Comparison
For the Biotechnology subindustry, Telescope Innovations's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telescope Innovations 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Telescope Innovations's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Telescope Innovations's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in May. 2026 and 3-year before.
Telescope Innovations (TELIF) has a 3-Year RORE % of 38.10 as of May. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Telescope Innovations and its competitors. According to the industry distribution chart, Telescope Innovations ranks #154 out of 1291 companies in the Biotechnology industry, placing it in the top 11.9%.
Is Telescope Innovations' 3-Year RORE % too high?
Telescope Innovations' current 3-Year RORE % is 38.10. Based on the distribution chart, Telescope Innovations ranks #154 out of 1291 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Telescope Innovations has a GF Score™ of 27/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Telescope Innovations' 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Telescope Innovations ranks #154 out of 1291 companies for 3-Year RORE %. This places Telescope Innovations in the top 12% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Telescope Innovations and its competitors. Telescope Innovations's current 3-Year RORE % is 38.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telescope Innovations stock overvalued right now?
Based on GuruFocus' analysis, Telescope Innovations (TELIF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.38, compared to a current price of $0.47 — trading 22.4% above its estimated fair value. The current 3-Year RORE % is 38.10. Telescope Innovations' overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Telescope Innovations (TELIF), the current 3-Year RORE % is 38.10 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telescope Innovations (TELIF) Overvalued in 2026?
Based on GuruFocus' analysis, Telescope Innovations stock appears to be overvalued.
The current stock price of $0.47 is trading 22.4% above its estimated GF Value™ of $0.38.
GuruFocus considers Telescope Innovations to be Modestly Overvalued.
Key valuation signals for TELIF:
3-Year RORE %: 38.10
GF Value™: $0.38 vs. price of $0.47 (22.4% above fair value)
No single metric tells the full story. See the TELIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telescope Innovations Corp is a technology company focused on development as a Contract Research Organization (CRO) to develop intellectual property, provide contract research, and build automation products, and operates as a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. Its flagship product is the DirectInject-LC system. The Company operates in a single operating segment and generates revenue from three streams: contract research services, grant income, and the sale of automation products, with the majority of revenue derived from automation product sales from customer contracts. It operates in Canada, the United States, Europe, and Asia, with the majority of revenue coming from the United States.
27GF Score
Get the complete analysis for TELIF
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TELIF has been successfully added to your 
